RCKT vs. EWTX, SDGR, AVDL, ARDX, JANX, HROW, VERA, AMPH, SNDX, and ETNB
Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Edgewise Therapeutics (EWTX), Schrodinger (SDGR), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Janux Therapeutics (JANX), Harrow (HROW), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry.
Rocket Pharmaceuticals vs. Its Competitors
Edgewise Therapeutics (NASDAQ:EWTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.
In the previous week, Edgewise Therapeutics had 1 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 8 mentions for Edgewise Therapeutics and 7 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 1.14 beat Edgewise Therapeutics' score of 1.09 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.
Edgewise Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Edgewise Therapeutics' return on equity of -30.65% beat Rocket Pharmaceuticals' return on equity.
Edgewise Therapeutics presently has a consensus price target of $40.55, suggesting a potential upside of 182.55%. Rocket Pharmaceuticals has a consensus price target of $16.73, suggesting a potential upside of 410.16%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Edgewise Therapeutics.
98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 23.2% of Edgewise Therapeutics shares are held by insiders. Comparatively, 24.8% of Rocket Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Edgewise Therapeutics beats Rocket Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Rocket Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rocket Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:RCKT) was last updated on 9/1/2025 by MarketBeat.com Staff
Free RCKT Stock Alerts